Citigroup
TLOG

Citigroup’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Citigroup’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-275
Closed – – 7755
2016
Q1 		$0 Buy
+275
New +$76 ﹤0.01% 8053
2014
Q4 		– Sell
-854
Closed -$4K – 7498
2014
Q3 		$4K Buy
+854
New +$3.98K ﹤0.01% 6691
2014
Q1 		– Sell
-1,226
Closed -$12K – 7352
2013
Q4 		$12K Buy
+1,226
New +$9.57K ﹤0.01% 6373

Other funds holding TLOG

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Citigroup's TLOG Position: Q2 2016 in Review

Citigroup sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2016, closing a stake of 275 shares.

Citigroup first reported a position in TLOG in Q4 2013 and held it in 3 quarters. The position peaked at $12K in Q4 2013. 19 funds tracked by Wall St. Rank hold TLOG as of Q2 2016.

  • Citigroup reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2016 after selling out during the quarter.
  • Citigroup sold 275 TetraLogic Pharmaceuticals Corporation shares in Q2 2016.
  • Citigroup first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 3 quarters.
  • Citigroup's TetraLogic Pharmaceuticals Corporation position peaked at $12K in Q4 2013.
  • 19 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2016.

Based on Citigroup's 13F filing for Q2 2016, filed 12 Aug 2016.